Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial

We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15–30). Mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayo, Ashley J., Browne, Erica N., Montgomery, Elizabeth T., Torjesen, Kristine, Palanee-Phillips, Thesla, Jeenarain, Nitesha, Seyama, Linly, Woeber, Kubashni, Harkoo, Ishana, Reddy, Krishnaveni, Tembo, Tchangani, Mutero, Prisca, Tauya, Thelma, Chitukuta, Miria, Gati Mirembe, Brenda, Soto-Torres, Lydia, Brown, Elizabeth R., Baeten, Jared M., van der Straten, Ariane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222015/
https://www.ncbi.nlm.nih.gov/pubmed/33713213
http://dx.doi.org/10.1007/s10461-021-03205-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222015/
https://www.ncbi.nlm.nih.gov/pubmed/33713213
http://dx.doi.org/10.1007/s10461-021-03205-z

Ejemplares similares